State Street Corp Has $2.63 Million Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS)

State Street Corp grew its stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 4.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,732,221 shares of the company’s stock after purchasing an additional 69,180 shares during the period. State Street Corp owned approximately 1.38% of Atossa Therapeutics worth $2,633,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of ATOS. Renaissance Technologies LLC grew its position in Atossa Therapeutics by 11.9% in the second quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock valued at $1,846,000 after acquiring an additional 164,540 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Atossa Therapeutics by 3,160.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after purchasing an additional 399,041 shares during the last quarter. Rhumbline Advisers bought a new stake in shares of Atossa Therapeutics in the 2nd quarter worth about $161,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Atossa Therapeutics during the 3rd quarter worth about $75,000. Finally, SG Americas Securities LLC lifted its holdings in Atossa Therapeutics by 254.3% during the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after purchasing an additional 30,037 shares during the last quarter. 12.74% of the stock is owned by institutional investors and hedge funds.

Atossa Therapeutics Trading Down 3.1 %

Shares of NASDAQ ATOS opened at $0.94 on Wednesday. Atossa Therapeutics, Inc. has a 1-year low of $0.77 and a 1-year high of $2.31. The company has a 50-day moving average of $1.25 and a two-hundred day moving average of $1.31. The company has a market cap of $118.77 million, a PE ratio of -4.29 and a beta of 1.21.

Wall Street Analyst Weigh In

Several analysts have weighed in on ATOS shares. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Atossa Therapeutics in a research note on Thursday, December 12th. Ascendiant Capital Markets increased their price target on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, StockNews.com downgraded Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, November 18th.

Atossa Therapeutics Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.